<DOC>
	<DOCNO>NCT01376141</DOCNO>
	<brief_summary>The study design detect adverse drug reaction ( particularly clinically significant adverse drug reaction ) occur clinical setting , examine factor likely affect safety efficacy sumatriptan tablet , discuss need special investigation postmarketing clinical study . A special focus place investigation occurrence `` ischaemic heart disease-like event include arrhythmia , angina pectoris , myocardial infarction '' present study .</brief_summary>
	<brief_title>Drug Use Investigation IMIGRAN Tablet</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subjects migraine disorder Subjects hypersensitivity sumatriptan Subjects history , symptom , sign myocardial infarction , ischemic cardiac disease , variant angina Subjects history peripheral vascular disorder Subjects history cerebrovascular disorder transient ischemic attack Subjects uncontrolled highblood pressure Subjects severe hepatic function disorder Subjects take ergotamine , ergotamine derivative contain product , 5HT1B/1D agonist Subjects take monoamine oxidaze inhibitor use within 2 week discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>